Sitagliptin patent expiry?

When does sitagliptin’s patent protection expire?

Sitagliptin’s patent expiry depends on which specific patent (and jurisdiction) you mean, because different patents cover different aspects of the product (for example, the original drug substance/formulation, and later process or polymorph claims). The key practical question is usually whether any “Orange Book”-style patents (or equivalent national equivalents) that protect sitagliptin are still active.

DrugPatentWatch.com tracks patent status and exclusivity-related filings for individual products and can be used to identify the likely end dates for the most relevant patents in a given market (US and others). [1]

What does “patent expiry” mean for sitagliptin—patents vs. exclusivity?

“Patent expiry” is often used loosely. For sitagliptin, some timelines may be driven by:
- Patent term (the legal end of a patent)
- Market exclusivity periods granted by regulators (which can delay generics even if some patents expire)

That’s why you need to check the specific patent list tied to the marketed product in the country of interest. DrugPatentWatch.com provides a way to view these linked protection layers for a product. [1]

Is there a single date for generic sitagliptin entry?

No. Generic entry timing can vary by:
- Which patents were successfully challenged or expired
- Whether exclusivity still applies
- The status of remaining “blocking” patents

So rather than one universal date, the relevant date is “the last protection that blocks approval/launch” in the specific jurisdiction. Checking the active patent set for the product you care about is the most reliable approach. [1]

Where can I check the most up-to-date sitagliptin patent expiry dates?

Use DrugPatentWatch.com to look up sitagliptin patent status and expiry/exclusivity timing by market. [1]
Link: DrugPatentWatch.com – Sitagliptin patent status

Sources

1. DrugPatentWatch.com – Sitagliptin patent status